Background: Adherence to American College of Chest Physicians (CHEST) and National Comprehensive Cancer Network (NCCN) guidelines for venous thromboembolism (VTE) prophylaxis helps avoid thromboembolic complications during hospitalization. Electronic health records (EHR) have the potential to make an impact on guideline adherence, but data are lacking. Objectives: To determine compliance with VTE prophylaxis guidelines in internal medicine and oncology populations and to determine whether EHR implementation had any effect on the rate and appropriateness of prophylaxis practices. Methods: A retrospective chart review was conducted on medical and oncology patients admitted to the hospital for a 2-month period pre-EHR and post-EHR implementation. Risk assessment tools were available pre and post, however they were not mandatory. The rate of VTE prophylaxis was compared between the 2 time periods, with appropriateness assessed in a subgroup of participants without prophylaxis. Results: A total of 2,423 patients on the oncology and internal medicine floors were identified during the pre-EHR (n = 1,171) and post-EHR (n = 1,252) time periods. Patients in the post-EHR group were less likely to be prescribed prophylaxis as compared to those in the pre-EHR group (43% vs 50%; P = .001). In the patients audited for proper prophylaxis use (n = 750), significantly more patients in the post-EHR group had risk factors (84% vs 53%; P < .001) and contraindications (23% vs 8%; P = .001) than in the pre-EHR group. Noncompliance to prophylaxis in patients who were candidates (positive risk factors without contraindications) occurred more often in the post-EHR group (51% vs 39%; P < .001). Conclusion: Implementation of an EHR was associated with an increase in the documentation of risk factors and contraindications; however, there was a significant decrease in VTE prophylaxis utilization after EHR implementation.
V enous thromboembolism (VTE) is a common occurrence in both internal medicine and oncology patients, and VTE during hospitalization accounts for one-fourth of all VTE events. 1 Hospitalization alone is associated with an 8-fold increased risk of VTE, and 50% to 75% of these events occur in patients on the internal medicine floor. 1 In a study of 1,180 inpatients, of whom 60.3% were categorized as low risk and 39.7% as high risk, it was found that VTE occurred in 11% of high-risk patients who did not receive prophylaxis. Only 0.3% of low-risk patients who did not VTE Prophylaxis Compliance and EMR Implementation receive prophylaxis experienced a VTE (hazard ratio [HR], 32.0; 95% CI, 4.1-251.0). 2 The American College of Chest Physicians (ACCP) recommends the Padua Prediction Score to assign risk stratification for VTE in hospitalized internal medicine patients to either high or low risk. 1 This stratification is based on factors such as active cancer, previous VTE, reduced mobility for at least 3 days, known thrombophilic condition, recent trauma, recent surgery, heart failure, respiratory failure, acute myocardial infarction, acute ischemic stroke, acute infection, obesity, and ongoing hormonal treatment. 2 Because cancer is a major risk factor, oncology patients are at an even greater risk of VTE during hospitalization; 3% to 12% experience VTE in their first hospitalization. 3 VTE increases the likelihood of death by 2-to 6-fold and is the most common cause of death at 30-day follow-up in cancer patients undergoing surgery. 3 The National Comprehensive Cancer Network guideline identifies additional risk factors based on cancer-and treatmentrelated factors. The specific cancers with the highest risk include pancreatic, brain, stomach, kidney, uterus, lung, ovary, bladder, and testis tumors. Treatment with certain antineoplastic (diethylstilbestrol, thalidomide, or lenalidomide) and hormonal compounds is also associated with an increased VTE risk in patients with cancer.
The risk for VTE must outweigh the risk of a major bleeding event in order for a patient to receive prophylaxis. For internal medicine patients, the major risk factors for a major bleeding event are active gastroduodenal ulcer, bleeding in the 3 months before admission, and platelet count less than 50 x 10 9 /L. 1 Oncology patients are typically at a higher risk of bleeding than internal medicine patients. In one study comparing 181 oncology patients and 661 non-oncology patients all receiving VTE prophylaxis, the 12-month cumulative incidence of major bleeding was 12.4% and 4.9%, respectively. 4 With the implementation of electronic health records (EHRs) and the ability to create VTE prophylaxis order sets, there is a more uniform and easily accessible way for physicians to order anticoagulation for their patients. To date, there are no studies that have examined the impact of EHR implementation on VTE prophylaxis.
The objective of this study was to determine compliance with VTE prophylaxis guideline recommendations in the internal medicine and oncology populations, and to determine whether the implementation of an EHR has any effect on the rate and appropriateness of exclusion of VTE prophylaxis use at St. Vincent Indianapolis Hospital. Our customizable EHR includes computer physician order entry and an electronic medication administration record with barcode verification. During the study period, the EHR was not used routinely for physician documentation, however it was used for allied health services documentation.
METHODS
A retrospective, institutional review boardapproved chart review was completed to meet the study objectives. All medical and oncology patients admitted to a community teaching hospital in a 2-month period pre-EHR implementation (November 1, 2011 to December 31, 2011) and a 2-month period post-EHR implementation (November 1, 2012 to December 31, 2012) were evaluated for compliance with VTE prophylaxis guidelines. The EHR was implemented in February 2012, allowing for a 9-month lead in period prior to evaluation of the post-EHR period. Patient treatment was classified as either compliant or noncompliant based on the CHEST guidelines for nonsurgical internal medicine patients and the NCCN guidelines for oncology patients ( Table 1) .
Compliance rates were compared between the 2 groups to determine whether the implementation of the EHR had any effect on the use of proper VTE prophylaxis. This compliance rate was calculated based on the entire population (pre-EHR and post-EHR). If a patient was prescribed VTE prophylaxis, it was assumed to be appropriate. A random sampling of 750 patients without prophylaxis, split between the 2 groups, was conducted to further determine the appropriateness of the lack of pharmacologic prophylaxis. Each patient eligible for evaluation was assigned a number, and our sample was determined using a random number generator. Electronic and paper charts were manually evaluated for the study endpoints in this sampling of patients. Patients were labeled as candidates for pharmacologic prophylaxis if they had positive risk factors for VTE without contraindications to pharmacologic prophylaxis. Contraindications to pharmacologic prophylaxis were based on drug, patient, and specific guideline factors ( Table 2) .
Eligibility Criteria
The study included all patients admitted to the oncology unit with an oncology diagnosis or seen by an oncology attending physician or patients admitted to the internal medicine units during the 2-month periods. Patients excluded were those younger than 18 years old, prisoners, and pregnant women.
Data Collection
Data collected included hospital room number, age, sex, receipt of anticoagulants, and receipt of mechanical VTE prophylaxis. Patients were evaluated to determine whether or not they received pharmacologic VTE prophylaxis. Subsequently, data were collected in a random sampling of patients not receiving pharmacologic prophylaxis and included demographics (pertinent diagnosis, history of bleeding and/or clotting disorders, age, sex, height, weight), indications for VTE prophylaxis, renal function (serum creatinine VTE Prophylaxis Compliance and EMR Implementation and creatinine clearance as calculated by the Cockcroft-Gault equation), use of mechanical prophylaxis, risk factors for VTE, and contraindications for pharmacologic VTE prophylaxis. This random sampling was evaluated to determine whether there was an appropriate reason for not initiating pharmacologic prophylaxis per CHEST and NCCN guidelines.
Data Analysis
The primary endpoint of the study was to determine the rates of VTE prophylaxis (pharmacologic or mechanical) pre-and post-EHR implementation. Secondary endpoints included the rate of noncompliance with pharmacologic prophylaxis (risk factors for VTE present, no contraindications present) in a random sampling of patients not receiving pharmacologic prophylaxis and the rate of risk factor and contraindication documentation. Subgroup analyses based on service (hematology/oncology, internal medicine, other) were conducted utilizing the above outcomes. Patients were placed into 2 groups (preand post-EHR implementation), and data were compared via the chi-square test for nominal data and Mann-Whitney U test for continuous, nonparametric data. Data were tested for normality via the Shapiro-Wilk test. Data were evaluated using IBM SPSS, version 22 (IBM Corp., Armonk, NY).
RESULTS
A total of 2,475 patients on the oncology and internal medicine floors were identified. Fifty-two patients were excluded due to incomplete data, which left an included population of 2,423 during the pre-EHR (n = 1,171) and post-EHR (n = 1,252) time periods. Overall, the median age of the population was 63 years, and the majority of the population was female (57% in the pre-and post-EHR groups). Prophylaxis (mechanical and pharmacologic) was utilized in 584 (50%) of the pre-EHR group and 539 (43%) of the post-EHR group (P < .0001) ( Table 3) .
In the analysis of the random sampling of patients receiving no pharmacologic prophylaxis (n = 750), 195 (53%) of the pre-EHR patients and 326 (85%) of the post-EHR patients had risk factors present that made them candidates for VTE prophylaxis (P < .001). Of these patients, 30 (10%) in the pre-EHR group and 90 (23%) in the post-EHR group had contraindications to pharmacologic prophylaxis (P < .001). Candidates for pharmacologic prophylaxis without contraindications who did not receive prophylaxis included 142 (39%) patients in the pre-EHR group and 195 (51%) patients in the post-EHR group (P < .001). Candidates for pharmacologic prophylaxis receiving mechanical prophylaxis were 34 (24%) in the pre-EHR group and 61 (31%) in the post-EHR group (P < .001) ( Table 4 ).
In the internal medicine subgroup of patients not receiving pharmacologic prophylaxis (n = 431; 185 pre-EHR, 246 post-EHR), risk factors were present in 75 (41%) and 204 (83%) patients in the pre-and post-EHR groups, respectively (P < .001) ( Table 4) . Statistically significant differences in the contraindications present before and after EHR implementation were found within the internal medicine subgroup (6.5% vs 27%; P < .001). Patients who were VTE candidates based on positive indications for pharmacologic prophylaxis without contraindications were less prevalent in the pre-EHR group than the post-EHR group (24% vs 45%; P < .001).
Likewise, in the hematology/oncology subgroup of patients not receiving pharmacologic prophylaxis (n = 186; 97 pre-EHR, 89 post-EHR), 64 (66%) patients in the pre-EHR group and 84 (94%) patients in the post-EHR group had risk factors present (P < .001), while 13 (13%) and 19 (21%) had contraindications, respectively (P = .151) ( Table   Table 3 . Demographics of patients identified for study inclusion: Pre-and post-implementation of electronic health records (EHRs) 
4).
Candidates for pharmacologic prophylaxis without contraindications who did not receive prophylaxis included 47 (48%) patients and 57 (64%) patients in the pre-and post-EHR groups, respectively (P = .032).
DISCUSSION
The results of this study indicate that the implementation of an EHR at a community teaching hospital was associated with a decrease in the use of VTE prophylaxis. Before this study, no studies evaluated the compliance rates of VTE prophylaxis before and after EHR implementation. There are data supporting the utilization of clinical decision support tools (CDST) within the EHR and their impact on VTE prophylaxis compliance. [5] [6] [7] Haut and colleagues conducted a study to examine documentation and compliance to guidelines in a trauma population before and after a mandatory risk factor stratification tool and orderset. 6 They found that both documentation and compliance increased following implementation (3% vs 97.8% and 66.2% vs 84.4%, respectively; P < .001). Novis and colleagues found a significant increase in compliance in a surgical population, however not to the same extent as the study by Haut and colleagues (14% vs 36%; P < .001). 4 Compared to the previous 2 studies, MaCauley and associates evaluated VTE prophylaxis compliance rates in a broader patient population that included medicine patients. 7 They assessed VTE prophylaxis compliance rates in patients categorized as low risk from their clinical decision support tool. Similar to surgical and trauma patient populations, there was a significant increase in the compliance rates after implementation (27% vs 34%; P < .0001). There is currently no published literature to support the use of CDST in the hematology and oncology population. The VTE risk assessment tool and order set included in our EHR were not mandatory upon the implementation of the EHR, and this may explain the differences in compliance rates between our study and published literature. This same assessment tool was available to be used both pre-and post-EHR implementation on either paper or in the EHR, respectively. The assessment tool included a list of common risk factors for VTE and placed the patients into a low-, moderate-, or high-risk category. There was space available for documentation of contraindications to pharmacologic VTE prophylaxis on both versions. Upon further investigation, we discovered that the VTE risk assessment tool in the EHR was not provider-friendly during the study period. This may have led to decreased pharmacologic prophylaxis orders in our post-EHR time period. We tried to eliminate any initial EHR difficulties and growing pains by starting our post-EHR time period 8 months after the system was adopted.
This was a single-center study with two, 2-month time frames. Because the data were collected over a short time frame, it is possible that many of the same physicians were working during both periods; the study may have missed the practice habits of physicians not on either service during the 2-month period. This could have introduced bias into the results, because some physicians may be more likely than others to prescribe VTE prophylaxis to their patients; however, it is unlikely that varying practice patterns would have resulted in a significant increase in the use of VTE prophylaxis. In future studies, it is recommended that data be collected over a longer period of time or that a random sampling of patients who were treated by different physicians be taken.
The percentage of patients who received mechanical prophylaxis may be falsely high. Often times when mechanical prophylaxis is ordered, the patients refuse to wear them. That being said, that percentage of patients who did not receive any prophylaxis, including mechanical, may be falsely low due to the possible lack to documentation of non-compliance. Unless it was documented in a clinical note that a patient was not using mechanical prophylaxis, we made the assumption that the patient was compliant.
Although rates of VTE prophylaxis decreased, after implementation of the EHR there was a statistically significant increase in the identification of contraindications to VTE prophylaxis and risk factors for development of VTE. We expected to see this increase but cannot conclude that the EHR makes it easier to identify risk factors and contraindications. Without further data collection on the entire population, we cannot determine whether the patient populations had similar baseline risk factors and contraindications or if the postimplementation group had a statistically significant difference in risk factors. Despite the increase in documented risk factors post-EHR implementation, the rate of prophylaxis decreased. We were also unable to determine whether or not the physicians viewed the risk factors and contraindications or whether they were aware of all the risk factors and contraindications to prophylaxis.
CONCLUSION
Implementation of the EHR at a community teaching hospital was associated with a decreased overall rate and appropriateness of VTE prophylaxis practices and an increase in risk factor and contraindication documentation. The implementation of an EHR with computerized physician order entry in itself will not ensure an increase in VTE prophylaxis rates. The passive availability of an order set without a mandatory risk assessment followed by CDSTs allowed practice to continue unchanged with a decline in prophylaxis rates. To increase the likelihood of success, CDSTs and mandatory assessment should be implemented within the EHR.
